TVTX vs. HROW, EPZM, OMER, RIGL, AMRX, AMPH, SMMT, VERA, GERN, and RCKT
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Harrow (HROW), Epizyme (EPZM), Omeros (OMER), Rigel Pharmaceuticals (RIGL), Amneal Pharmaceuticals (AMRX), Amphastar Pharmaceuticals (AMPH), Summit Therapeutics (SMMT), Vera Therapeutics (VERA), Geron (GERN), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "medical" sector.
Harrow (NASDAQ:HROW) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
Harrow has higher earnings, but lower revenue than Travere Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Harrow had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 6 mentions for Harrow and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.31 beat Harrow's score of 1.17 indicating that Harrow is being referred to more favorably in the media.
Harrow has a net margin of -22.59% compared to Harrow's net margin of -87.94%. Travere Therapeutics' return on equity of -39.82% beat Harrow's return on equity.
Harrow received 28 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 56.25% of users gave Harrow an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
72.8% of Harrow shares are owned by institutional investors. 13.7% of Harrow shares are owned by company insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Harrow has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Harrow currently has a consensus target price of $29.80, indicating a potential upside of 66.02%. Travere Therapeutics has a consensus target price of $15.58, indicating a potential upside of 110.02%. Given Harrow's higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Harrow.
Summary
Harrow beats Travere Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
